Specialties

MajesTEC results for teclistamab plus daratumumab in MM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Conference

ASH 2025

Type

News article

15 December 2025 11:38

First data from in vivo CAR T-cell therapy in MM

Presented By

Prof. Phoebe Joy Ho , University of Sydney, Australia

Conference

ASH 2025

Type

News article

15 December 2025 11:25

Off-the-shelf CAR T-cell product under investigation in B-cell NHL

Presented By

Dr Jingwei Yu , Tianjin Medical University, China

Conference

ASH 2025

Type

News article

11 December 2025 10:55

New frontline regimen for Ph+ ALL tested in phase 3

Presented By

Prof. Suning Chen , First Affiliated Hospital of Soochow University, China

Conference

ASH 2025

Type

News article

11 December 2025 10:52

Promising new combination therapy for FL

Presented By

Dr Lorenzo Falchi , Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASH 2025

Type

News article

11 December 2025 10:37

New frontline therapy for AML?

Presented By

Prof. Amir Fathi , Harvard Medical School, MA, USA

Conference

ASH 2025

Type

News article

11 December 2025 10:33

Fixed-duration or continuous treatment for CLL?

Presented By

Dr Othman Al-Sawaf, University Hospital of Cologne, Germany

Conference

ASH 2025

Type

News article

9 December 2025 16:17

KITE-363 and KITE-753 fly far in LBCL

Presented By

Prof. Saurabh Dahiya, Stanford University School of Medicine, CA, USA

Conference

ASH 2025

Type

News article

9 December 2025 16:14

Does earlier cilta-cel treatment improve outcomes in MM?

Presented By

Prof. Luciano Costa , University of Alabama, AL, USA

Conference

ASH 2025

Type

News article

9 December 2025 16:11

Promising data for a novel, innovative bispecific antibody in MM

Presented By

Prof. Jin Lu , Peking University People’s Hospital, China

Conference

ASH 2025

Type

News article

9 December 2025 16:08

Clinically meaningful and durable response of mosunetuzumab in MZL

Presented By

Dr Tara Graff, Mission Cancer and Blood, IA, USA

Conference

SOHO 2025

19 September 2025 16:51

Acalabrutinib Added to Bendamustine-Rituximab Improves Outcomes in High-Risk Untreated Mantle Cell Lymphoma

Presented By

Dr Victoria Otero , AstraZeneca, Gaithersburg, USA

Conference

SOHO 2025

19 September 2025 16:48

Glofitamab Shows High and Durable Remissions in Heavily Pretreated Mantle Cell Lymphoma

Presented By

Dr Estefania Mulvihill, F. Hoffman-La Roche, Switzerland

Conference

SOHO 2025

19 September 2025 16:45

Fixed-Duration Subcutaneous Mosunetuzumab Achieves High Response Rates and PK Non-Inferiority in Relapsed or Refractory Follicular Lymphoma

Presented By

Volker Wibking, MD , Genentech, CA, USA

Conference

SOHO 2025

19 September 2025 16:36

Epcoritamab Demonstrates Durable 3-Year Responses in Relapsed or Refractory Follicular Lymphoma

Presented By

Yasmin Karimi, MD

Conference

SOHO 2025

19 September 2025 16:32

Unravelling real-world safety and effectiveness of axi-cel in LBCL

Presented By

Dr Dasom Lee, Stanford University, CA, USA

Conference

EHA 2025

18 June 2025 11:23

inMIND: Positive phase 3 results for tafasitamab combination in FL

Presented By

Prof. Marek Trneny, Charles University, Czech Republic

Trial

Phase 3, inMIND

Conference

EHA 2025

18 June 2025 11:20

ELM-2: Survival benefit for patients with FL on odronextamab

Presented By

Prof. Stefano Luminari, University of Modena and Reggio Emilia, Italy

Trial

Phase 2, ELM-2

Conference

EHA 2025

18 June 2025 11:19

HCT Frailty Scale may refine allo-HCT selection process

Presented By

Dr Maria Queralt Salas, Hospital Clinic de Barcelona, Spain

Conference

EHA 2025

17 June 2025 10:36

RedirecTT-1: Dual antigen-targeting treatment associated with promising efficacy in EMD myeloma

Presented By

Dr Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, RedirecTT-1

Conference

EHA 2025

17 June 2025 10:30

Large pooled analysis reveals prognostic utility of circulating tumour cells in MM

Presented By

Dr Luca Bertamini, University of Turin, Italy

Conference

EHA 2025

17 June 2025 10:29

GAIA/CLL13: Positive 5-year efficacy outcomes for GIV in CLL

Presented By

Dr Arnon Kater, Amsterdam UMC, the Netherlands

Trial

Phase 3, GAIA, CLL13

Conference

EHA 2025

16 June 2025 10:58

TUSCANY: Promising data for addition of tuspetinib in untreated chemo-ineligible AML

Presented By

Dr Gabriel Mannis, Stanford University, CA, USA

Trial

Phase 2, TUSCANY

Conference

EHA 2025

16 June 2025 10:55

STARGLO: Long-term clinical benefits of Glofit-GemOx over R-GemOx in DLBCL

Presented By

Dr Gareth Gregory, Monash University, Australia

Trial

Phase 3, STARGLO

Conference

EHA 2025

16 June 2025 10:52

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Prof. Laurie Sehn, University of British Columbia, Canada

Trial

Phase 3, inMIND

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:34

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Presented By

Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA; Dr Sameh Gaballa, Lee Moffitt Cancer Center, FL, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:31

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

Presented By

Dr Catherine Diefenbach, NYU Langone Health, NY, USA

Trial

Phase 1, BO42203

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:29

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands

Trial

Phase 1/2, ATALANTA-1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:27

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:25

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:23

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Presented By

Prof. Mark Levis, Johns Hopkins University, MD, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:20

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Presented By

Dr Ghayas Issa, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2, SAVE

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:17

Venetoclax plus azacitidine in young patients with AML

Presented By

Dr Daniel Pollyea, University of Colorado, CO, USA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:14

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

Presented By

Dr Jennifer Marvin-Peek, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:12

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

Presented By

Dr Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:09

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Presented By

Dr Ioannis Mantzaris, Montefiore Medical Center, NY, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:07

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Prof. Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:05

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:03

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:57

KCRd offers overall survival benefit over CRd in newly diagnosed MM

Presented By

Dr Charlotte Pawlyn, Institute of Cancer Research, UK

Trial

Phase 3, Myeloma XI/XI+

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:53

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:49

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

Trial

Phase 1/2, CA057-003

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:47

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

Trial

Phase 3, IFM2017-03

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:44

CEPHEUS: Further support for daratumumab regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, CEPHEUS

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:42

Meet the Trialist: Prof. Mats Jerkeman on the ALTAMIRA trial

Expert

Prof. Mats Jerkeman, Skane University Hospital and Lund University, Sweden

Trial

Phase 2, ALTAMIRA

Conference

ASH 2024

23 December 2024 15:15

Meet the Expert: Prof C. Ola Landgren discusses the value of real-world evidence

Expert

Prof. C. Ola Landgren, Sylvester Comprehensive Cancer Center, University of Miami, FL, USA

Conference

ASH 2024

23 December 2024 15:07

Reclassification of AML Subtypes and Risk in Light of ICC and ELN2022

17 September 2024 13:51

The landscape of TP53 mutations and their prognostic impact in CLL

Presented By

Dr Consuelo Bertossi, University Hospital Ulm, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 15:11

Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis

Presented By

Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL

Presented By

Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain

Trial

Phase 3, PhALLCON

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Prof. Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, TUD-APOLLO-064

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Excellent phase 3 results for asciminib in chronic myeloid leukaemia

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:24

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Post-intensification data confirm superiority of quadruple therapy in MM

Presented By

Prof. Marc Raab, University Hospital Heidelberg, Germany

Trial

Phase 3, GMMG-HD7

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Promising phase 1 results for novel CAR T-cell therapy in MM

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:16

Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients

Expert

Samantha Nier, Acute Leukemia Advocates Network

1 August 2024 14:16

Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials

Expert

Prof. C. Ola Landgren, University of Miami, FL, USA

Conference

EHA 2024

10 July 2024 16:53

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

Second-line therapy for multiple myeloma: Where we are now?

Presented By

Dr Francesca Gay, University of Torino, Italy

Conference

EMN 2024

23 April 2024 11:56

Treatment choices beyond immunotherapy in relapsed/refractory multiple myeloma

Presented By

Dr Rakesh Popat, University College London Hospitals, UK

Conference

EMN 2024

23 April 2024 11:42

The state of toxicities for immunotherapy for multiple myeloma

Presented By

Dr Alfred Garfall, University of Pennsylvania, PA, USA

Conference

EMN 2024

23 April 2024 11:39

Early multiple myeloma: where are immunotherapies headed?

Presented By

Dr Elias K. Mai, University Hospital Heidelberg, Germany

Conference

EMN 2024

23 April 2024 11:34

How does resistance arise for immunotherapy in relapsed/refractory multiple myeloma?

Presented By

Dr Nizar Bahlis, University of Calgary, Canada

Conference

EMN2024

23 April 2024 11:27

Functional imaging to complement bone marrow MRD in multiple myeloma

Presented By

Dr Elena Zamagni, Bologna University, Italy

Conference

EMN 2024

22 April 2024 13:04

Mass spectrometry detection of MRD for patients with multiple myeloma

Presented By

Dr Joannes F. M. Jacobs, Radboud University Medical Center, the Netherlands

Conference

EMN 2024

22 April 2024 13:02

Is MRD testing ready for prime time in multiple myeloma?

Presented By

Prof. Edward A. Stadtmauer, University of Pennsylvania, PA, USA

Conference

EMN 2024

22 April 2024 12:59

Managing transplant-ineligible elderly and frail patients with multiple myeloma

Presented By

Dr Salomon Manier, University of Lille, France

Conference

EMN 2024

22 April 2024 12:57

Treatment should be tailored to frailty status in patients with transplant-ineligible newly diagnosed multiple myeloma

Presented By

Dr Sara Bringhen, University of Torino, Italy

Conference

EMN 2024

22 April 2024 12:53

Interview: Advancing Myeloma Care

Expert

Prof. Monique Minnema, UMC Utrecht, the Netherlands

19 March 2024 14:42

Impact of Treatment on Multiple Myeloma Outcomes: Real-World Experience

19 March 2024 14:29

FLT3-ITD-specific MRD assessment useful for clinical management of AML

Presented By

Prof. Alexander Perl, University of Pennsylvania, PA, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:05

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL

Presented By

Prof. Martin Schrappe, Hong Kong College of Paediatricians, China

Trial

Phase 3, AIEOP-BFM ALL 2017

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Promising results for olverembatinib in combination with venetoclax for Ph+ ALL

Presented By

Dr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By

Dr Moritz Fürstenau, University of Cologne, Germany

Trial

Phase 2, CLL2-BAAG

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:01

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By

Dr Paolo Strati, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, SYMPATICO

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

KdD outperforms Kd in R/R MM also in participants with poor renal function

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, CANDOR

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:58

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34